1.1. Integrating accurate non-invasive surveillance methods, technologies and/or biomarkers for recipient care strategies
and EARLY identification of the onset of acute cellular rejection (ACR), antibody-mediated rejection (AMR) and/or
cardiac allograft vasculopathy (CAV).

1.2. Developing improved therapeutics and/or therapeutic strategies for acute cellular rejection (ACR), antibody-mediated
rejection (AMR) and/or cardiac allograft vasculopathy (CAV).

1.3. Developing novel immunotherapies, identification of novel targets for immunosuppression, improving methods for
monitoring and determining the optimal level of immunosuppression to prevent ACR, AMR, and/or CAV while
reducing/eliminating secondary conditions that may arise due to immunosuppression (e.g., renal; infectious).

1.4. Developing and validating experimental models to study the underlying mechanisms, therapies, and/or prevention of
CAV.

1.5. Developing more evidence-based person-centered post-transplant care guidelines, including nutrition and exercise
guidelines

2.1. Improving transitioning from pediatric to adult care/medication adherence.

2.2. Development of evidence-based tools for improving pediatric heart recipient and family education related to heart
transplantation.

2.3. Improving evidence-based diverse psycho-social support methods including technologies, hosted peer action groups,
virtual visit models and remote metrics.

3.1. Applying advanced data analytics to better integrate extracardiac and cardiovascular candidate risk factors including
degree of multiorgan dysfunction and frailty, race and ethnic group, and HLA and non-HLA sensitization.

3.2. Innovative strategies that would improve organ availability, matching, utilization, and allocation.

3.3. Pre-transplant modifications in donor heart immunogenicity.

3.4. Promotion of evidence-based optimization and standardization of pre-transplant protocols including donor selection and
management.

3.5. Pediatric scaled xenotransplantation and/or tissue engineering.